T. Rowe Price Investment Management, Inc. Repligen Corp Transaction History
T. Rowe Price Investment Management, Inc.
- $166 Billion
- Q3 2024
A detailed history of T. Rowe Price Investment Management, Inc. transactions in Repligen Corp stock. As of the latest transaction made, T. Rowe Price Investment Management, Inc. holds 27,710 shares of RGEN stock, worth $4.07 Million. This represents 0.0% of its overall portfolio holdings.
Number of Shares
27,710
Previous 510,616
94.57%
Holding current value
$4.07 Million
Previous $64.4 Million
93.59%
% of portfolio
0.0%
Previous 0.04%
Shares
9 transactions
Others Institutions Holding RGEN
# of Institutions
488Shares Held
54.2MCall Options Held
341KPut Options Held
235K-
Black Rock Inc. New York, NY7.57MShares$1.11 Billion0.02% of portfolio
-
Price T Rowe Associates Inc Baltimore, MD6.39MShares$939 Million0.11% of portfolio
-
Vanguard Group Inc Valley Forge, PA5.04MShares$741 Million0.01% of portfolio
-
State Street Corp Boston, MA1.62MShares$239 Million0.01% of portfolio
-
Champlain Investment Partners, LLC Burlington, VT1.42MShares$209 Million1.34% of portfolio
About REPLIGEN CORP
- Ticker RGEN
- Exchange NASDAQ
- Sector Healthcare
- Industry Medical Instruments & Supplies
- Shares Outstandng 55,491,200
- Market Cap $8.15B
- Description
- Repligen Corporation develops and commercializes bioprocessing technologies and systems for use in biological drug manufacturing process in North America, Europe, the Asia Pacific, and internationally. It offers Protein A ligands that are the binding components of Protein A affinity chromatography resins; and cell culture growth factor products....